The Novartis business model is built on a singular premise: discover or acquire breakthrough medicines, develop them through rigorous clinical validation, and commercialize them globally at premium prices that reflect their therapeutic value. This is not a commodity business — it is a high-stakes, high-reward model that requires simultaneous excellence in science, regulation, manufacturing, and commercial execution. At its core, Novartis generates revenue through the sale of patented pharmaceutical products across its priority therapeutic areas: oncology, cardiovascular-renal-metabolic, immunology, neuroscience, and ophthalmology. These are areas of significant unmet medical need where the company has built durable expertise, and where reimbursement systems in major markets have historically supported premium pricing for genuinely differentiated therapies. The revenue model operates on a patent-protected window of typically 10–15 years per product, during which the company can generate returns sufficient to fund the next wave of R&D. The economics are asymmetric — most drugs in development fail, but the successes must generate returns large enough to cover the full portfolio of failures. Novartis manages this by maintaining a large, diverse pipeline and by pursuing medicines in areas where regulatory pathways and clinical proof-of-concept are well understood. Pricing strategy is a critical lever. In the United States, Novartis negotiates with pharmacy benefit managers and payers using a value-based framework — the price of a drug reflects its clinical outcomes relative to existing standards of care. In Europe, the company navigates health technology assessment processes in each country, often accepting lower prices in exchange for broader access. In emerging markets, tiered pricing and local manufacturing partnerships allow participation without eroding global price anchors. Beyond direct product sales, Novartis generates value through licensing agreements, co-development partnerships, and milestone payments from collaborations with biotech companies. The company has historically been an active business development participant — acquiring companies and assets that complement its internal pipeline rather than building everything from scratch. The 2019 acquisition of The Medicines Company for $9.7 billion, which brought inclisiran (a twice-yearly cholesterol-lowering injection) into the portfolio, is a prime example of this external innovation model. Manufacturing is a strategic asset, not merely a cost center. Novartis operates advanced manufacturing facilities for small molecules, biologics, and increasingly, cell and gene therapies. The Novartis technical operations network spans Switzerland, Germany, Ireland, Singapore, the United States, and India, with each site specialized for particular product types and regulatory environments. The company's investment in radioligand therapy manufacturing — including its Eckert & Ziegler facility acquisitions and dedicated RLT sites — reflects a deliberate bet that targeted radiopharmaceuticals will become a major oncology platform. The commercial model is physician-focused for specialty medicines, with highly trained medical science liaisons and specialty sales forces engaging oncologists, cardiologists, neurologists, and rheumatologists. For products like Kymriah — the world's first CAR-T cell therapy, approved in 2017 — Novartis developed an entirely new commercial infrastructure, including certified treatment centers and outcome-based contracting with payers, setting industry precedent for how transformative therapies can be brought to market. Digital transformation is reshaping the business model at multiple levels. Novartis has invested in AI-driven drug discovery through its Novartis Institutes for BioMedical Research, partnered with Microsoft and other technology companies for data analytics in clinical trials, and deployed digital health tools to improve patient adherence and real-world evidence generation. These investments are not peripheral — they are intended to accelerate the timeline from scientific discovery to patient access, which is the ultimate driver of competitive advantage. The post-Sandoz Novartis is a leaner, more focused organization. The removal of a large, lower-margin generics business has structurally improved the company's margin profile. Operating margins in the innovative medicines segment typically exceed 35%, compared to the mid-teens in generics. This margin expansion thesis is central to the investment case and to management's strategic rationale for the spin-off. In aggregate, the Novartis business model is a high-investment, high-return cycle: deploy capital into R&D and acquisitions, generate blockbuster revenues from successful therapies, reinvest in the next generation, and return surplus capital to shareholders. It is a model that requires patience, scientific credibility, and global commercial infrastructure — and Novartis has all three.